Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma
Urszula N. Wasko(Revolution Medicines (United States)), Kenneth P. Olive(Columbia University Irving Medical Center), Marie Ménard(University of California, San Francisco), Kristina Drizyte‐Miller(University of North Carolina at Chapel Hill), Yu Chi Yang(Revolution Medicines (United States)), Gulam A. Manji(NewYork–Presbyterian Hospital), Matthew Holderfield(Revolution Medicines (United States)), Stephen A. Sastra(Columbia University Irving Medical Center), Elsa Quintana(Revolution Medicines (United States)), Jacqueline A.M. Smith(Revolution Medicines (United States)), Julien Dilly(Massachusetts Institute of Technology), Yingyun Wang(Revolution Medicines (United States)), David Wildes(Revolution Medicines (United States)), Robert H. Vonderheide(University of Pennsylvania), Priya S. Hibshman(University of North Carolina at Chapel Hill), Jennifer A. Roth(Broad Institute), Jingjing Jiang(Revolution Medicines (United States)), Ben Z. Stanger(Cancer Research Institute), Mallika Singh(Revolution Medicines (United States)), Samantha B. Kemp(University of Michigan), Margo Orlen(UPMC Hillman Cancer Center), Michael A. Badgley(Columbia University Irving Medical Center), Basil Bakir(University of Pennsylvania), Channing J. Der(University of North Carolina at Chapel Hill), Matthew G. Rees(Broad Institute), Stephanie Chang, John A. Chabot(Columbia University Irving Medical Center), Lingyan Jiang(Hainan University), Michael D. Kluger(Columbia University Irving Medical Center), Amanda R. Decker-Farrell(Columbia University Irving Medical Center), Andrew J. Aguirre(Broad Institute), Rina Sor(University of Pennsylvania), Haley Courtney(Revolution Medicines (United States)), Marie C. Hasselluhn(Columbia University Irving Medical Center), Carmine F. Palermo(Columbia University Irving Medical Center), Cynthia Clendenin(University of Pennsylvania), Yevgeniy Gindin(Revolution Medicines (United States)), Ruiping Zhao(Hebei North University), Bianca J. Lee(Revolution Medicines (United States)), Ciara Helland(Revolution Medicines (United States)), Will Vostrejs(Cancer Research Institute), Zhengping Wang(Shandong University), Amber A. Amparo(University of North Carolina at Chapel Hill), Melissa M. Ronan(Broad Institute), Alvaro Curiel-Garcia(Columbia University Irving Medical Center), Tanner C. Dalton(Columbia University Irving Medical Center)
Cited by 11
Related Papers
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Efficient tumour formation by single human melanoma cells
|Nature|2008|1.8k
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k
The Death Domain Kinase RIP Mediates the TNF-Induced NF-κB Signal
|Immunity|1998|1.1k
Activated Kras and <i>Ink4a/Arf</i> deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
|Genes & Development|2003|1k